Cagrilintide

Human clinical development

The guide reports once-weekly dosing in human development.

Context: Trial-specific indication and formulation; primary identifier not supplied. Route is not specified in this imported entry.

Limitations: Combination use with retatrutide is not an established regimen.

Route: Not documented

• Peptide Protocol Field Guide · version 7

Human SC PK in renal and hepatic impairment

Two single-dose studies found no consistent AUC or Cmax differences across renal or hepatic impairment groups.

Context: Adults with renal impairment (0.6 mg SC; n=33) or hepatic impairment (0.9 mg SC; n=32) versus normal-function groups; DOI 10.1007/s40262-026-01654-0; NCT04209049 and NCT05564104.

Limitations: Small severe-impairment groups (n=5 renal; n=4 hepatic); within-route comparisons do not estimate absolute or oral bioavailability or support extrapolation to other analogues or combinations.

Route: SC · AUC0-infinity ratios vs normal: renal mild 1.23, moderate 1.18, severe 1.21; hepatic mild 0.99, moderate 1.01, severe 1.11. Cmax and Tmax assessed; route-specific absolute bioavailability not established.

• Nielsen et al. Human cagrilintide PK in renal and hepatic impairment ↗

Clinical-development weekly pattern

Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.

Context: Human

Human study regimen: Frequency: Once weekly; Route: Not documented; Species: Human

Limitations: Trial identifier, route, amount and duration are not supplied. Does not establish a retatrutide combination regimen.

Route: Not documented

• Peptide Protocol Field Guide · version 7